Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) shares fell 6.2% during trading on Friday . The stock traded as low as $13.31 and last traded at $13.61, with a volume of 252,810 shares traded. The stock had previously closed at $14.51.

Several research firms have commented on ADMS. Credit Suisse Group AG reaffirmed a “buy” rating and set a $21.00 price target on shares of Adamas Pharmaceuticals in a research report on Monday, July 25th. Noble Financial reaffirmed a “buy” rating and set a $25.00 price target on shares of Adamas Pharmaceuticals in a research report on Friday, July 22nd. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 price target on shares of Adamas Pharmaceuticals in a research report on Wednesday, July 20th. Mizuho reaffirmed a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Thursday, June 23rd. Finally, JMP Securities reaffirmed a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. Adamas Pharmaceuticals currently has an average rating of “Buy” and an average target price of $32.00.

The firm’s 50 day moving average price is $15.53 and its 200-day moving average price is $15.82. The firm’s market cap is $295.86 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.11. Analysts anticipate that Adamas Pharmaceuticals Inc. will post ($3.09) EPS for the current year.

An institutional investor recently raised its position in Adamas Pharmaceuticals stock. Dimensional Fund Advisors LP raised its position in shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 585.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 69,411 shares of the specialty pharmaceutical company’s stock after buying an additional 59,285 shares during the period. Dimensional Fund Advisors LP owned approximately 0.38% of Adamas Pharmaceuticals worth $1,966,000 at the end of the most recent reporting period.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.